Vident Advisory LLC Boosts Position in Stryker Co. (NYSE:SYK)

Vident Advisory LLC lifted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,873 shares of the medical technology company's stock after acquiring an additional 2,001 shares during the period. Vident Advisory LLC's holdings in Stryker were worth $6,795,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $30,000. BankPlus Trust Department acquired a new stake in shares of Stryker during the 4th quarter worth about $33,000. Finally, Activest Wealth Management acquired a new stake in shares of Stryker during the 4th quarter worth about $36,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

Shares of Stryker stock opened at $394.63 on Tuesday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market cap of $150.63 billion, a PE ratio of 50.85, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The business has a 50-day simple moving average of $367.24 and a 200-day simple moving average of $375.80.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period in the previous year, the company posted $2.50 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is 45.41%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on SYK shares. Truist Financial raised their price objective on Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. Argus set a $450.00 price objective on Stryker in a research report on Monday, February 3rd. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Roth Mkm raised their price objective on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Finally, The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $427.05.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.